An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.
The rare disease bile duct cancer is set to be carved up by genetic subtype, and will see two targeted treatments filed soon.
Last week's pivotal trial success could give Celgene a second AML drug, setting up a battle against Roche's Venclexta and idasanutlin.
Novo Nordisk hopes that its attempt to preserve beta cells will fare better than Caladrius’s, while Aslan tries its hand at DHODH inhibition.
The commercial potential of last year’s new medicines suggests another strong year of productivity from biopharma, while a further analysis reveals the arrival of two…
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?
Deal adds a marketed small molecule and three pipeline agents, although Lilly will share revenue from Vitrakvi and LOXO-195 with Bayer.
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
The $5bn transaction was surely only made possible by shrinking valuations, but investors in both Glaxo and Tesaro have reasons to be unhappy.